Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
This piece contrasts fee structures across popular index funds to help you pick the one with the lowest ongoing costs.
24,420 articlesTeva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
A brookings paper just accidentally released ties county AI exposure to voting shifts, offering a new lens on New Yor...
Marvell Technology has bold dreams about joining the trillion-dollar club. This article lays out a practical timeline...
AI data centers are pushing bandwidth limits, lifting demand for photonics. This report examines five notable players...
This article dives into why this dividend stock's moat offers unparalleled stability for long-term investors. Discove...
Two very different tech plays collide in 2026: Innodata edges into AI data preparation, while Workiva anchors large e...
Two very different aerospace players compete for a spot on ambitious investors' lists. Archer Aviation aims to redefi...
Coca-Cola and Philip Morris International both beat expectations in Q1 2026 and now sit near 52-week highs. Analysts ...
In 2026, investors face a classic showdown: a rapid-growth dermatology
Two drone-focused names—Red Cat Holdings and Unusual Machines—face off for investors. This guide breaks down the mark...
Two AI pioneers sit on the public markets' doorstep with wall-high expectations. This guide breaks down which giant—a...
A notable stake by Starboard Value in Fluor hints at renewed confidence in the industrial cycle. This article explain...